Does Aetna (CVS Health) Cover Armour Thyroid?

What Is Armour Thyroid and Why Do Patients Request It?

Armour Thyroid is a prescription natural desiccated thyroid (NDT) extract derived from porcine thyroid glands. Each grain (60 mg) contains approximately 38 mcg levothyroxine (T4) and 9 mcg liothyronine (T3), making it biochemically distinct from synthetic levothyroxine alone [1]. The FDA approved Armour Thyroid for the treatment of hypothyroidism, myxedema, and as an adjunct to surgery and radioiodine therapy for thyroid cancer [2].

The clinical argument for NDT centers on T3 delivery. Synthetic levothyroxine depends on peripheral conversion of T4 to T3 via deiodinase enzymes, and roughly 15 to 20 percent of hypothyroid patients carry a DIO2 gene variant (Thr92Ala polymorphism) that reduces this conversion efficiency [3]. For these patients, adding a direct T3 source may improve cognitive and metabolic outcomes.

The landmark Hoang et al. trial (J Clin Endocrinol Metab, 2013; N=70) found that 49% of hypothyroid patients preferred desiccated thyroid extract over levothyroxine after a blinded crossover period, and patients on NDT lost an average of 4 lbs more than those on levothyroxine at equivalent TSH suppression [4]. A 2019 systematic review in Frontiers in Endocrinology examining five randomized trials confirmed that a meaningful subset of patients reports superior quality of life on combination T3/T4 therapy compared with T4 monotherapy [5].

The American Thyroid Association's 2014 guidelines acknowledge that "some patients may prefer thyroid extracts" and that individualization of therapy is appropriate, though levothyroxine remains the standard first-line treatment [6]. This guideline language is the clinical foundation most endocrinologists use when seeking Aetna prior authorization for Armour Thyroid.

How Does Aetna (CVS Health) Classify Armour Thyroid on Its Formulary?

Aetna places Armour Thyroid on Tier 3 (non-preferred brand) across most of its 2024-2025 commercial PPO, HMO, and CVS Caremark-administered formularies. Tier 3 status means the drug is covered but carries a higher cost-sharing requirement than Tier 1 generic alternatives such as levothyroxine sodium [7].

Levothyroxine generics sit on Tier 1 with $0 to $10 copays on most Aetna plans. Armour Thyroid at Tier 3 typically carries a $50 to $90 copay per 30-day supply after the deductible is met, depending on the specific employer plan design. Some Aetna individual and family plans negotiated through the ACA marketplace place Armour Thyroid on Tier 4 (specialty or non-preferred), which can raise out-of-pocket cost to 30 to 50 percent coinsurance [8].

The easiest way to confirm your specific plan's tier status is to use the Aetna member portal at aetna.com or call the Member Services number on the back of your insurance card and ask for the CVS Caremark formulary lookup specific to your plan year. Formularies change annually on January 1, and a drug can move tiers between plan years without individual member notice.

Because Aetna's pharmacy benefit is administered through CVS Caremark, the formulary search tool at caremark.com also reflects Aetna-administered plans when your plan ID is entered [9]. Checking both portals reduces the chance of receiving outdated tier information.

Does Aetna Require Prior Authorization for Armour Thyroid?

Yes. Prior authorization (PA) is required for Armour Thyroid on virtually all Aetna commercial plans. The PA process for this drug is rated moderate-to-high difficulty because Aetna's clinical policy aligns with ATA guidelines placing levothyroxine as first-line therapy.

Aetna's standard PA criteria for thyroid hormone replacement agents generally require the prescribing clinician to document all of the following:

1. A confirmed diagnosis of primary, secondary, or tertiary hypothyroidism supported by TSH and free T4 lab values.
2. A documented trial of levothyroxine at an adequate dose (typically 6 to 12 weeks at goal-titrated dose) with inadequate symptom response despite TSH within reference range, OR documented intolerance to synthetic levothyroxine (adverse reaction, allergy, or absorptive disorder such as celiac disease or post-bariatric malabsorption).
3. A clinical note from the treating physician explaining why Armour Thyroid is medically necessary over continued synthetic monotherapy.

Aetna's internal clinical policy bulletins reference evidence standards from the American Association of Clinical Endocrinologists (AACE) and the ATA [6][10]. The AACE/ATA 2012 joint guidelines state that "the preponderance of evidence supports levothyroxine as the treatment of choice" but also that patient-reported outcome data warrant individualized decision-making [10]. Citing this exact language in the PA request letter has improved approval rates in HealthRX clinical workflows.

The PA submission must come from the prescribing physician's office (not the patient) and should include the ICD-10 diagnosis code (E03.9 for hypothyroidism, unspecified; E03.8 for other specified hypothyroidism), relevant TSH and free T4 lab results from the past 12 months, and a letter of medical necessity. Aetna has up to 72 hours to render an urgent PA decision and up to 15 calendar days for a standard (non-urgent) PA [11].

What Step Therapy Does Aetna Require Before Approving Armour Thyroid?

Step therapy is Aetna's standard requirement for Armour Thyroid coverage. Step therapy means the plan requires the patient to try and fail at least one preferred (Tier 1 or Tier 2) alternative before the higher-tier drug will be authorized.

For Armour Thyroid, the required step is a documented levothyroxine trial. Aetna typically requires evidence that the patient used levothyroxine for a minimum of 6 to 12 weeks at a clinically adequate, TSH-guided dose. "Failure" is defined as persistent hypothyroid symptoms (fatigue, cognitive impairment, weight gain, cold intolerance) despite a TSH within the laboratory reference range (generally 0.5 to 4.5 mIU/L), which some endocrinologists interpret as residual T3 deficiency [3][4].

Several states have passed step therapy override laws that require insurers to grant exceptions when a physician certifies that step therapy is clinically inappropriate for a specific patient. As of 2024, 30 states plus the District of Columbia have enacted step therapy laws that apply to state-regulated commercial insurance [12]. Aetna's fully-insured commercial plans in those states must honor a physician's exception request when supported by clinical documentation. Self-funded ERISA employer plans are generally exempt from state step therapy laws, though many large employers have voluntarily adopted similar exception policies.

If a patient is already stable on Armour Thyroid prescribed by a prior physician, Aetna may grant a continuity-of-care exception allowing coverage to continue for 90 days while a long-term PA is processed [13]. This is worth requesting at the time of plan enrollment to avoid a coverage gap.

How Do I Get Prior Authorization Approved for Armour Thyroid with Aetna?

Approval hinges on the quality and specificity of the clinical documentation submitted with the PA request. A PA that simply says "patient prefers Armour Thyroid" will be denied. A PA that documents a specific clinical rationale supported by published evidence and patient-specific lab data is far more likely to succeed.

The strongest PA requests include the following components: the patient's diagnosis with ICD-10 code, TSH and free T4 values over time showing the treatment course, a description of symptoms that persisted on optimized levothyroxine, any relevant genetic or absorptive factors (DIO2 polymorphism testing, celiac disease serology, post-surgical anatomy), and a direct citation of the Hoang et al. 2013 data showing that 49% of hypothyroid patients preferred NDT over levothyroxine in a randomized crossover design [4].

Peer-reviewed literature supports T3 measurement as a useful adjunct to TSH monitoring. A 2020 analysis published in Thyroid (PMID 31880526) found that free T3 levels in patients on levothyroxine monotherapy were consistently lower than in euthyroid controls, suggesting incomplete hormone replacement in a subset of patients [14]. Including a patient's free T3 result alongside TSH in the PA request gives the reviewing physician clinical context that T4-only dosing may be genuinely insufficient.

Aetna assigns a physician reviewer to evaluate each PA. Requesting a peer-to-peer call between the treating endocrinologist or internist and the Aetna medical reviewer is one of the single most effective steps available. Published data from the American Medical Association's 2022 Prior Authorization Physician Survey found that 84% of peer-to-peer calls resulted in PA approval or modification [15]. Peer-to-peer requests must typically be made within 2 business days of the initial denial notice.

How Do I Appeal an Aetna Denial for Armour Thyroid?

Aetna denials for Armour Thyroid are common on the first submission, particularly when step therapy documentation is incomplete. A denial is not final. Federal law under the ACA (29 CFR 2590.715-2719) guarantees at least one internal appeal and one independent external review for any adverse benefit determination on a non-grandfathered health plan [16].

The internal appeal process works as follows. After receiving the denial letter, the patient or provider submits a written appeal within 180 days (Aetna's standard window). The appeal letter should directly rebut each stated reason for denial, attach all clinical documentation that was not included in the original PA, and request that Aetna's internal review be conducted by a physician with relevant specialty training (endocrinology or internal medicine). Aetna must render an internal appeal decision within 30 days for pre-service appeals and 60 days for post-service appeals [11][16].

If the internal appeal is denied, the patient has the right to an independent external review conducted by an Independent Review Organization (IRO) not affiliated with Aetna. External review decisions are binding on the insurer under federal and most state laws [16]. The National Association of Insurance Commissioners model act and state external review laws require IROs to apply generally accepted clinical standards, which means the Hoang et al. evidence and ATA guideline language supporting individualized therapy become directly relevant [6][4].

A second parallel strategy is filing a complaint with the state insurance commissioner's office. Aetna is licensed in all 50 states and is subject to state market conduct examinations. A formal complaint creates a documented regulatory record and often prompts expedited internal review.

For patients enrolled in Aetna Medicare Advantage plans, a separate appeals pathway exists through the CMS Medicare appeals process, which includes a Qualified Independent Contractor (QIC) review at the second level [17]. Medicare Advantage plans have additional formulary exception rights under 42 CFR 423.578 when a physician certifies that the formulary alternative (levothyroxine) is not as effective or causes adverse effects [17].

What Does Armour Thyroid Cost Without Aetna Coverage?

If the PA is denied and all appeals are exhausted, cash-pay options are available. The average retail cash price for Armour Thyroid 60 mg (a 30-day supply at one grain daily) is approximately $85 at major chain pharmacies when using a discount card such as GoodRx or RxSaver [18]. This compares with a manufacturer list price near $180 per month and a typical insured copay of $50 to $90 at Tier 3.

Generic desiccated thyroid products (NP Thyroid by Acella Pharmaceuticals and Nature-Throid by RLC Labs) carry lower cash prices, often $40 to $60 per month, and are bioequivalent to Armour Thyroid in T4 and T3 content per grain. Switching to a generic NDT may also satisfy Aetna's formulary preference rules if the generic version appears at a lower tier, so checking the formulary for NP Thyroid separately is worthwhile [19].

The Armour Thyroid manufacturer (AbbVie, which acquired the product through Allergan) does not currently offer a patient assistance program equivalent to some branded drugs. However, AbbVie's myAbbVie Assist program covers select products, and patients should confirm Armour Thyroid's current eligibility directly at abbvie.com/patients [20]. Manufacturer savings cards are generally not stackable with federal insurance (Medicare, Medicaid) but can be used with commercial plans including Aetna to reduce the Tier 3 copay.

Does Aetna Cover Armour Thyroid for Thyroid Cancer Patients?

Thyroid cancer patients on suppressive thyroid hormone therapy represent a distinct clinical population. Post-thyroidectomy TSH suppression is a guideline-recommended strategy to reduce recurrence risk in intermediate and high-risk differentiated thyroid cancer [21]. The American Thyroid Association's 2015 thyroid cancer management guidelines recommend maintaining TSH below 0.1 mIU/L in high-risk patients during active surveillance [21].

Armour Thyroid is less commonly used for TSH suppression than synthetic levothyroxine because the T3 component makes precise TSH targeting more variable. Most endocrinologists managing post-thyroidectomy suppression prefer levothyroxine for this indication. Aetna's PA criteria for Armour Thyroid in thyroid cancer patients will still require clinical documentation of why NDT is medically appropriate over levothyroxine suppressive therapy, and approval is less predictable in this setting [2][21].

Practical Checklist Before Submitting an Aetna PA for Armour Thyroid

Before the prescriber's office submits the PA, confirm that the following items are ready. Missing any one of these is the most common reason for a first-submission denial.

• Confirmed ICD-10 diagnosis code (E03.9 or appropriate specified code)
• TSH and free T4 labs from within the past 6 months
• Free T3 lab result if available (supports T3 deficiency argument) [14]
• Documentation of levothyroxine trial: dates, doses, TSH response, and persistent symptoms
• Physician letter of medical necessity citing Hoang et al. 2013 [4] and ATA guideline individualization language [6]
• State step therapy override request if applicable (check your state's law status at ncsl.org)
• Peer-to-peer call request submitted simultaneously [15]

Submitting all of these components in the first PA request reduces the likelihood of a denial requiring an appeal, which can delay treatment access by 30 to 90 days.